Resignations Amidst Crisis: Kobayashi Pharmaceutical Probes 80 Deaths Linked to Products

In a significant shake-up at Kobayashi Pharmaceutical, two top executives have resigned as the company investigates 80 deaths potentially linked to its products. President Akihiro Kobayashi and Chairman Kazumasa Kobayashi, both descendants of the founding family, have stepped down to “clarify executive responsibility” concerning the issue tied to the company’s beni kōji fermented rice products.

The company first became aware of the potential health risks in January when a doctor reported several cases of kidney problems among patients using the products. This prompted an immediate recall of five items in March and the establishment of a customer advice hotline. Reports from affected customers included symptoms such as changes in urine color, limb swelling, and fatigue.

Further investigation revealed the presence of a potentially toxic acid produced by mould at one of Kobayashi Pharmaceutical’s factories. This discovery has raised serious concerns about the safety of beni kōji, which is made from rice fermented with monascus purpureus, a reddish-purple mould. Though widely marketed as a health supplement for managing high cholesterol and blood pressure, beni kōji is also traditionally used as a food dye.

In response to the crisis, the company’s board of directors has expressed deep sorrow, extending condolences to the families of those who died. “We pray for the deceased and offer our heartfelt apologies to our customers and business partners,” the board stated.

Recommended Articles

India Tycoon Ambani’s Son’s Lavish Wedding Kicks Off in Mumbai

Pharmacy Council Cautions Public Against Sale of Unlicensed Medicines

Taking the helm as the new president is Satoshi Yamane, previously the head of sustainability policy. Despite stepping down as president, Akihiro Kobayashi will remain involved in the company to oversee compensation arrangements for those affected. He has publicly acknowledged his commitment to addressing the harm caused to customers.

The incident underscores the critical importance of stringent quality control measures in pharmaceutical manufacturing and the potential consequences of lapses in product safety. Kobayashi Pharmaceutical’s swift action in recalling products and initiating an investigation, along with the leadership changes, reflect the company’s efforts to restore trust and ensure consumer safety.

Source BBC